GC7 Sulfate is an inhibitor of deoxyhypusine synthase (DHPS).

GC7 treatment for 72 hours significantly reduces cell viability of MYCN2 (±Dox) and BE(2)-C cells in a dose-dependent way, with concentrations ranging from 0.1 to 100 μM. In MYCN2 cells, 5 μM of GC7 results in a reduction of cell viability by approximately 40% to 60% compared to untreated controls, while BE(2)-C cells need 25 μM to achieve a 50% decrease. At 10 and 100 μM concentrations, GC7 notably lowers levels of total retinoblastoma (Rb), phosphorylated Rb, and Cdk4 protein while increasing p21 protein levels. GC7 induces minimal cytotoxicity in HCC cells at concentrations between 0 and 20 μM, whereas higher concentrations from 50 to 100 μM considerably reduce the viability of all tested HCC cell lines. After treatment with 20 μM GC7, the synthesis of new 3 H-labeled hypusine of eIF5A1/eIF5A2 is rarely observed, in contrast to untreated cells. Additionally, the incorporation of [3 H]-spermidine into HCC cells is significantly decreased with GC7 concentrations of 20 μM or more.